Wedbush Estimates argenx's Q1 Earnings (NASDAQ:ARGX)

argenx SE (NASDAQ:ARGX - Free Report) - Analysts at Wedbush lifted their Q1 2025 earnings per share (EPS) estimates for shares of argenx in a report issued on Thursday, October 31st. Wedbush analyst D. Nierengarten now anticipates that the company will earn $1.91 per share for the quarter, up from their previous estimate of $1.83. Wedbush currently has a "Outperform" rating and a $560.00 target price on the stock. The consensus estimate for argenx's current full-year earnings is ($0.36) per share. Wedbush also issued estimates for argenx's Q2 2025 earnings at $2.23 EPS and Q3 2025 earnings at $2.62 EPS.

ARGX has been the subject of several other research reports. JPMorgan Chase & Co. increased their price objective on shares of argenx from $640.00 to $670.00 and gave the company an "overweight" rating in a research note on Monday. Barclays upgraded shares of argenx from an "equal weight" rating to an "overweight" rating in a report on Tuesday, August 6th. HC Wainwright raised their price objective on argenx from $533.00 to $617.00 and gave the company a "buy" rating in a report on Friday. Guggenheim upped their target price on argenx from $585.00 to $665.00 and gave the stock a "buy" rating in a report on Friday. Finally, Citigroup increased their target price on argenx from $512.00 to $635.00 and gave the company a "buy" rating in a research report on Thursday, October 17th. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $598.44.

argenx Trading Down 1.2 %

NASDAQ ARGX traded down $6.91 during trading on Monday, hitting $588.67. 265,734 shares of the company's stock were exchanged, compared to its average volume of 309,067. The company has a market cap of $35.20 billion, a PE ratio of -668.94 and a beta of 0.61. argenx has a fifty-two week low of $327.73 and a fifty-two week high of $610.73. The stock's 50 day moving average price is $539.46 and its two-hundred day moving average price is $467.19.

argenx (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings results on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 0.96% and a negative net margin of 2.11%. The company had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same quarter last year, the company posted ($1.25) EPS.

Institutional Trading of argenx

Several large investors have recently made changes to their positions in the company. Blue Trust Inc. raised its stake in argenx by 620.0% during the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company's stock worth $28,000 after buying an additional 62 shares during the period. J.Safra Asset Management Corp increased its holdings in shares of argenx by 590.0% during the second quarter. J.Safra Asset Management Corp now owns 69 shares of the company's stock valued at $30,000 after acquiring an additional 59 shares in the last quarter. GAMMA Investing LLC raised its position in shares of argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company's stock worth $51,000 after purchasing an additional 40 shares during the period. Point72 Hong Kong Ltd bought a new position in shares of argenx in the 2nd quarter worth $76,000. Finally, Cromwell Holdings LLC grew its position in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company's stock valued at $85,000 after purchasing an additional 66 shares during the period. 60.32% of the stock is currently owned by institutional investors and hedge funds.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.